Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03763838
Other study ID # UMCC 2018.130
Secondary ID HUM00143509W81XW
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date October 7, 2019
Est. completion date June 18, 2024

Study information

Verified date June 2024
Source University of Michigan Rogel Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see if accupressure can help reduce the severity of fatigue experienced by ovarian cancer patients. Acupressure involves applying mild to moderate physical pressure by fingers, hand or a device to specific points on the skin to try to bring about a change in the body's functioning, in this case relief from chronic fatigue.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 170
Est. completion date June 18, 2024
Est. primary completion date June 18, 2024
Accepts healthy volunteers No
Gender Female
Age group 21 Years and older
Eligibility Inclusion Criteria: - Women aged 21 and older - Diagnosis of ovarian cancer, stages I to IV - Have average persistent fatigue defined a >=4 on the Brief Fatigue Inventory. - Fatigue must have started at or after the diagnosis of ovarian cancer - Completed all primary cancer treatments (surgery, chemotherapy at least 6 months prior), except maintenance therapies - No other planned interventions for fatigue other than current stable medication Exclusion Criteria: - Medically unstable - Acupuncture or acupressure receipt in past year - Have a diagnosis of untreated mood disorder, e.g., bipolar or major depressive disorder - Have a current diagnosis of anemia - Have a current untreated diagnosis of hypothyroidism - Have an initiation, a cessation or change of treatment of any chronic medications, dietary supplements, behavioral therapy, physical therapy, etc., or any planned change of medications, supplements or therapies during the study - Have the possibility of becoming pregnant

Study Design


Intervention

Other:
Acupressure
Six weeks of daily self-administered relaxing acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. These are points that are recognized as effective in Traditional Chinese Medicine (TCM).
Sham acupressure
Six weeks of daily self-administered sham acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure; however, the points that participants are instructed to use are not known to have any effect on the body.
Standard of Care
Fatigue management provided by participants' health care providers.

Locations

Country Name City State
United States University of Michigan Rogel Cancer Center Ann Arbor Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Michigan Rogel Cancer Center United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in level of fatigue at week 6 Self-reported on the Brief Fatigue Inventory (BFI) Baseline to week 6
Primary Change in level of fatigue up to week 24 Self-reported on the Brief Fatigue Inventory (BFI) Baseline up to week 24
Secondary Change in quality of life at week 6 Self-reported on the Functional Assessment of Cancer Therapy Ovarian (FACT-O) Baseline to week 6
Secondary Change in quality of life up to week 24 Self-reported on the Functional Assessment of Cancer Therapy Ovarian (FACT-O) Baseline up to week 24
Secondary Change in sleep quality at week 6 Self-reported on the Pittsburgh Sleep Quality Index (PSQI) Baseline to week 6
Secondary Change in sleep quality up to week 24 Self-reported on the Pittsburgh Sleep Quality Index (PSQI) Baseline up to week 24
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2